GeoVax is soaring over 50% in premarket trading, following WHO's declaration of mpox as a global health emergency, signaling its first-mover advantage in vaccine development.
GeoVax, a clinical-stage biotech focused on vaccine development, stands out following news from WHO about mpox, indicating potential for significant market impact and investor interest.
Collection
[
|
...
]